NASDAQ: RANIRani Therapeutics Holdings Inc Stock
$0.53-0.03 (-5.36%)
Updated Jun 13, 2025
RANI Price
$0.53
Fair Value Price
N/A
Market Cap
$30.21M
52 Week Low
$0.46
52 Week High
$4.37
P/E
-0.53x
P/B
-9.89x
P/S
35.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.20M
Earnings
-$29.80M
Gross Margin
100%
Operating Margin
-2,093.25%
Profit Margin
-2,483.2%
Debt to Equity
-9.65
Operating Cash Flow
-$34M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RANI Overview
Rani Therapeutics Holdings, Inc. is as a clinical stage biotherapeutics company developing orally administered biologics. Its product pipeline includes RT-101 for the treatment of neuroendocrine tumors and acromegaly, RT-105 to treat psoriatic arthritis, and RT-102 to treat osteoporosis. The company is also developing the RaniPill capsule, a platform intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani Therapeutics was incorporated in 2012 and is headquartered in San Jose, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RANI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RANI
Ranked#348 of 464
Ranked#348 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important RANI news, forecast changes, insider trades & much more!
RANI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RANI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RANI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RANI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
RANI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more RANI due diligence checks available for Premium users.
Valuation
RANI fair value
Fair Value of RANI stock based on Discounted Cash Flow (DCF)
Price
$0.53
Fair Value
-$0.74
Undervalued by
171.24%
RANI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RANI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.53x
Industry
-108.97x
Market
31.36x
RANI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.89x
Industry
4.66x
RANI's financial health
Profit margin
Revenue
$172.0k
Net Income
-$7.3M
Profit Margin
-4,223.3%
RANI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RANI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$24.1M
Liabilities
$29.5M
Debt to equity
-9.65
RANI's short-term liabilities ($20.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RANI's short-term assets ($17.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RANI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RANI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
$18.2M
Financing
-$3.7M
RANI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RANI vs Biotech Stocks
Rani Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.